Crossmark

Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?

Crossref DOI link: https://doi.org/10.1038/s41391-022-00585-8

Published Online: 2022-09-01

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Klaassen, Zachary http://orcid.org/0000-0001-7392-8916
Howard, Lauren http://orcid.org/0000-0003-3355-4483
Wallis, Christopher J. D. http://orcid.org/0000-0002-5990-4026
Janes, Jessica L. http://orcid.org/0000-0002-0560-0748
De Hoedt, Amanda http://orcid.org/0000-0002-3899-7702
Aronson, William J. http://orcid.org/0000-0003-2107-5362
Polascik, Thomas J.

Amling, Christopher J.

Kane, Christopher J. http://orcid.org/0000-0002-8769-2112
Cooperberg, Matthew R.

Terris, Martha K.

Wu, Yuan http://orcid.org/0000-0001-8925-555X
Freedland, Stephen J.
License Information

Text and Data Mining valid from 2022-09-01

Version of Record valid from 2022-09-01
More Information

Article History

Received: 11 June 2021

Revised: 10 July 2022

Accepted: 15 August 2022

First Online: 1 September 2022

Competing interests

: ZK: Pfizer/Astellas, Bayer; SJF: Pfizer, Astellas, Janssen, Bayer, Astra Zeneca, Merck, Myovant, Clovis, Sanofi, Exact Sciences, Decipher Biosciences, Tempus, Exosome, Boston Scientific. The rest of the authors declare no competing interests.

Document is current

Any future updates will be listed below